首页> 外文期刊>Journal of Medical Case Reports >Rivaroxaban as an effective alternative to warfarin in a patient with atrial fibrillation, thrombophilia, and left atrial appendage thrombus: a case report
【24h】

Rivaroxaban as an effective alternative to warfarin in a patient with atrial fibrillation, thrombophilia, and left atrial appendage thrombus: a case report

机译:利伐沙班在房颤,血栓形成和左心耳血栓形成的患者中可替代华法林

获取原文
           

摘要

BackgroundAtrial fibrillation is the most common cardiac arrhythmia. It is responsible for up to 20% of all ischemic strokes. Rate control and anticoagulation are crucial for atrial fibrillation management and stroke prevention. Case presentationWe present the case of an 84-year-old Italian?woman with a left atrial appendage thrombus that developed despite her use of anticoagulant therapy with warfarin for a previous pulmonary embolism. She had atrial fibrillation and heterozygosity for both factor V Leiden and methylenetetrahydrofolate reductase C677T mutation, thus creating resistance to activated protein C. Anticoagulant therapy was switched to heparin for 1 week and then to rivaroxaban. After 3 months of rivaroxaban use, the thrombus disappeared. ConclusionsThis case raises the issue of the ineffectiveness of warfarin therapy in complex cases involving particular thrombophilic conditions and the possibility of using rivaroxaban as a safe and effective alternative.
机译:背景心房颤动是最常见的心律不齐。它负责所有缺血性卒中的20%。速率控制和抗凝对于房颤管理和中风预防至关重要。病例介绍我们报道了一名84岁的意大利妇女,尽管她曾使用华法林进行抗凝治疗,但由于先前的肺栓塞而发生了左心耳血栓形成。她因V因子Leiden和亚甲基四氢叶酸还原酶C677T突变而出现房颤和杂合性,因此对活化蛋白C产生抗性。抗凝治疗改为肝素治疗1周,然后改为利伐沙班。使用利伐沙班3个月后,血栓消失。结论该病例引起了在涉及特殊血栓形成性疾病的复杂病例中华法林治疗无效的问题,并提出了利伐沙班作为安全有效替代方法的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号